A privately held start-up company, Syntellix, has announced the first Mg-alloy (WE43-based) screw for bone correction osteotomy in foot surgery. http://syntellix.com/en/news/ http://syntellix.com/en/products/ the latest clinical paper: http://www.biomedical-engineering-online.com/content/12/1/62
隔着 NIH几条街，联邦政府买单让我来学习对医学研究有益的技能，DoubleTree宾馆里看着争论，该相信谁呢？该相信郝炘所介绍的NIH官方回复，还是肖传国反驳？经常怀疑并不一定是坏事，而一味肯定一定不是什么好事。学习几个术语，可能更能加深理解临床试验的准则和要求。 第一：protocol，研究方案：这是临床试验的法定条文，所有的研究内容、实施方案都要体现在这个本本上，而该方案能否通过需要几层审批。最基本的是大学或医院的伦理委员会，简称（IRB）。如果是新药研究，即便是验证“老药新用”也必须获得FDA批发的IND；而显然肖氏手术的Nerve Rerouting Treatment for Neurogenic Bladder inSpina Bifida（NCT01096459)这一研究方案没有被NIDDK所采纳，而这一方案递交的时间应该是2013年1月，应该改进的、新的方案，这与此前批准实施的研究方案应该是不一样的，没有通过NIH及外部专家的评审，而这个方案没有通过的原因是: The experts thought that the proposed trial and itsprimary outcome measures were inadequately designed. 换一句话说，研究方案设计存在缺陷，而任何一个临床试验，只有一个关键，那就是：primary outcome，也就是解决唯一的、用一句话概括的关键问题。 第二：primary outcome，主要设定结果。开展临床试验的关键是用来证明一个假设是否成立，是获得可以用来否定与不否定这个假设的关键数据，或者事实。值得注意，临床试验获得的实验结果或数据用来形成进行统计学分析，最后得出结论，否定与不否定假设，而不是肯定某个假设。所以临床实验的设计必须获得足以进行统计学分析的数据，标本量，分析方法，主要观察数据等等。而NCT01096459新方案的主要设定结果：抓抓手术侧的皮肤能让膀胱产生15cm水柱以上的压力，而未手术侧的不能。 （ The primary aim of this study is reproducible bladder contraction of 15cm/H20 or more with scratching the cutaneous dermatome and no significant contraction with stimulation of the non-operated side ）这是对肖氏手术进行效果评价的指标。同时标出术后6至24个月之后，手术是安全的。 . 在对主要设定结果的设计中，可能protocol没有达到同行的要求。要理解，这个临床试验是case series研究，而不是case-control 研究，做这样的试验，没有对照，压力大大啊！而且是一个Open Label，没有双盲，研究者自己评估自己的手术是否有显著性意义，你说这个压力大不大！！美国在1950年代的时候做过类似的临床试验，那就是脊髓灰质炎灭活疫苗（Salk疫苗），全民接种，几乎没有对照，可是那试验是罗斯福总统私募基金做的，跟NIH毫无关系。NIH的回复其实很含糊，根本没有谈将来会不会再启动资助，完全有可能principle investigator修改研究方案，继续申请NIH基金。 第三：Safety，安全性。NIH的回答根本没有说安全性问题，而是肯定NIH没有说过肖氏手术是安全的。在美国开展临床试验，安全性可是大头，每一个试验都要在方案中提前预见安全性及任何可能的副作用。抽血的风险就是minimal risk，因为受试者会有疼痛，可能会形成血肿，可能会引起出血和感染，这只是抽血。而肖氏手术是invasive procedure，也就是有创性的手术，而且在一个手术被认定处于试验阶段的时候，受试者可能获得的利益没有，研究方案或者知情同意书中如果写受试者可能获益（改善膀胱功能），这样的方案通过不了IRB的审查。而在可预见的风险里面：疼痛、疤痕、麻醉意外、出血、感染、神经瘤、神经损伤等等，这些都是major risk。尽管风险中没有死亡，但是死亡不是唯一的风险，一个病人如果试验之后一个月，走路不小心骨折，这也是不良反应。而且肖氏手术的受试者以儿童为主，这其中还牵涉到“易伤害人群，vulnerable population”，其伦理要求只会更加严格。肖氏手术的在现阶段的伦理价值之下，在权衡风险和利益比重之下，benefit/risk ratio，肖氏手术的美国临床试验之路依然充满崎岖与艰辛。 NIH的答复给肖氏手术最好的出路， more animal studies areneeded to demonstrate that the created reflex arc improves voiding. Ifthose are positive, then more mechanistic studies in animals would be needed toexplain how the arc functions， 更多的动物试验、更深入的机制研究。肖氏手术一定是中国医学史上重要的一笔，不管是美丽的，还是丑陋的。 ref： 美国NIH回答撤销肖氏手术临床试验的有关问题 http://blog.sciencenet.cn/blog-714-724252.html http://clinicaltrials.gov/ct2/show/NCT0109645
科学网网友 许培扬 上月曾就美国撤销肖氏手术临床试验的事情发过一篇博文，后来不知是否由于肖传国提出异议而撤掉了。 肖传国在科学网发博文“ NIH 扩大评估肖氏手术有效病种，继续资助肖氏手术研究” http://blog.sciencenet.cn/home.php?mod=spaceuid=385748do=blogid=713793 对为什么撤销临床研究做了解释。肖的博文还给出他称之为“真实情况”的一个网页链接 http://www.clinicaltrials.gov/ct2/results?term=rerouting 上述链接的网页上有两项临床试验与肖氏手术有关，一个名为 Lumbar to Sacral Ventral Nerve Re-Routing ( 临床试验识别号 NCT00378664) 仍在进行中，但不再招募患者。这是 2006 年开始的一项私人基金支持的研究，不是被撤销的临床试验。 被撤销的临床试验的识别号是 NCT01096459 ，名称为 Nerve Rerouting Treatment for Neurogenic Bladder in Spina Bifida 。这是美国政府出资支持的研究。由于对肖氏手术的争议，美国国家糖尿病暨消化系统及肾脏疾病研究所 (NationalInstitute of Diabetes, Digestive and Kidney Diseases, 简称 NIDDK) 在 2010 年底暂停了该临床试验，要求对治疗方法做进一步的评估。 《科学》曾对要求重新评估做过报道：“来自中国的疑问给美国的临床试验带来麻烦”。 http://blog.sciencenet.cn/blog-714-380535.html 评估的结果导致了肖氏手术的临床试验上月被撤销。临床试验信息网站上给出的理由是 Protocol as presented by investigator was not approved by the NIDDK. 研究者提出的治疗方案未被 NIDDK 批准。 NIDDK 上周五回答了我就撤销临床试验提出的几个问题， 全部登载并翻译如下。 Q: Why was the proposal not approved? Was it safety concerns? What are the specific reasons? 问 : 为什么提出的治疗方案没有获得批准？是出于安全考虑吗？有哪些具体原因？ A: The Institute discussed the proposed study protocol (a prospective case-series study of surgical nerve rerouting in children with spina bifida) and received advice from experts at other institutes at NIH and an externalexpert panel. The experts thought that the proposed trial and its primary outcome measures were inadequately designed. After an extensive review, NIDDK decided not to fund the prospective case-series study of surgical nerve rerouting in children with spina bifida. 答 : 研究所讨论了该项目提出的治疗方案 ( 一项对脊柱裂儿童进行外科神经改道的前瞻性病例分析研究 ) ，收到了来自 NIH 内部其他研究所的专家、以及外部专家组的建议。专家们认为，研究提出的治疗方案、以及衡量其主要结果的指标设计不足。经过广泛评估之后， NIDDK 决定不支持这项对脊柱裂儿童进行外科神经改道的前瞻性病例分析研究。 Q: Now that the trial will not advance, will the trial continue to get funded? 问 : 现在临床试验不再进行，对这项临床研究的资助是否仍继续下去？ A: NIH is no longer funding the trial, “Nerve ReroutingTreatment for Neurogenic Bladder in Spina Bifida”. 答 : NIH 不再资助这项名为“ Nerve ReroutingTreatment for Neurogenic Bladder in Spina Bifida ”的临床试验。 Q: What will the money already received be used for? 问 : 项目已经得到的经费将如何使用？ A: The investigators at Beaumont Hospital in Royal Oak, Michigan, are able to use NIDDK funds to study the longer-term effects of nerve rerouting in children who had the nerve rerouting operation performed in a previous study that was not supported by the U.S. government. 答 : 密歇根州 RoyalOak 市的威廉 · 博蒙特医院的研究者能把来自 NIDDK 的经费用于研究儿童神经改道的长期效果上，这些儿童在此前一项不是由美国政府资助的研究中已经接受了神经改道的手术。 Q: What is NIDDK’s perspective regarding the nerve re-routing procedure? 问 : NIDDK 怎么看神经改道手术？ A: In addition to research on the long-term effects that the investigators will examine (described above ) , more animal studies are needed to demonstrate that the created reflex arc improves voiding. If those are positive, then more mechanistic studies in animals would be needed to explain how the arc functions. 答 : 除了上面提到对其长期效果的研究之外，还需要更多的动物研究来证实建立起来的反射弧改善了排尿。如果动物实验结果是肯定的，仍需要在动物身上进行更多的机制性研究，以解释反射弧如何工作的问题。 Q: Is the following statement, posted on Dr. Xiao’s blog, true or false? The NIH has affirmed the safety of the procedure and considered the number of surgeries carried out so far statistically sufficient; therefore, the planned trial which will enroll 15 additional patients has been withdrawn. The study will continue as planned with further funding for the next two years. 问 : 肖传国博士在其博客上写道：“ NIH 已经认定肖氏手术安全”，而且“认定现有 SB 肖氏手术例数及结果已足够得出统计学结论，本研究不需再增加病例数；所以将原计划请 NIH 出资再作 15 例的部分撤销，改成现在的题目和内容继续进行、资助。”请问这否属实？ A: No, NIH did not affirm the safety of the procedure or indicate that the number of surgeries is statistically sufficient. NIDDK feels the safety and efficacy of this experimental surgical intervention are unknown. 答 : 不属实。 NIH 没有认定过手术的安全性，或表示过已有的手术例数有统计学的意义。 NIDDK 认为用这个试验手术进行干预的安全性和效果尚属未知。
检索策略和检索结果： Found 56 studies with search of: 白血病 leukemia and 砒霜（三氧化二砷）arsenic trioxide 详细数据见： http://clinicaltrials.gov/ct2/results?term=leukemia+AND+arsenic+trioxidepg=1 Query Suggestions: The term, leukemia and arsenic trioxide, must be relaxed or trimmed to find documents Relax term to: leukemia AND arsenic trioxide leukemia AND arsenic trioxide Trim term to: arsenic trioxide arsenic trioxide Trim term to: leukemia leukemia Recognized Terms and Synonyms: leukemia and arsenic trioxide: 0studies arsenic trioxide: 97studies arsenic sesquioxide arsenous acid anhydride arsenous anhydride arsenous oxide as2o3 diarsenic trioxide naonobin trisenox white arsenic leukemia: 4274studies leucocythaemias leukemias trioxide: 111studies arsenic: 128studies as element Related Terms: Click on a related term to refine your search. This will narrow your search by adding an additional search term. If your search becomes too narrow (finds too few studies), broaden it by removing search terms with the Refine Search page. A acute promyelocytic leukemia aida regimen all trans retinoic acid apl apl-r arsenic sesquioxide arsenic trioxide arsenic(iii) oxide arsenous acid anhydride as2o3 aspergum aspirtab atra B buffex E easprin entaprin entercote F fab m3 G genacote genprin L leukemias acute promyelocytic leukemia M m3/m3 magnaprin minitabs N nrx 195183 P pml postremission therapy R rara T tamibarotene tretinoin trisenox V vesanoid Z zorprin 全部临床试验报告： study_fields.txt
全球临床试验研究项目计量分析报告 ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. ClinicalTrials.gov临床试验网 currently lists 137,539 studies 项目数量with locations in all 50 states and in 182 countries国家数量. ClinicalTrials.gov receives more than 95 million page views per month and 60,000 unique visitors daily 日访问量(as of February 2012). Contents Locations of Registered Studies Locations of Recruiting Studies Map of Studies Registered on ClinicalTrials.gov Types of Registered Studies Number of Registered Studies over Time Number of Registered Studies with Posted Results over Time Locations of Registered Studies This chart shows the distribution of locations for all studies registered on ClinicalTrials.gov. Total N = 137,539 studies (Data as of December 18, 2012) Legend for Recruiting Study location pie chart image Pie Color Location Non-U.S. Only (43%) U.S. Only (41%) Not Specified (9%) Both U.S. Non-U.S. (6%) Distribution of locations for all studies registered on ClinicalTrials.gov" Location Number of Registered Studies and Percentage of Total Non-U.S. Only 58,698 (43%) U.S. Only 56,983 (41%) Not Specified* 12,983 (9%) Both U.S. Non-U.S. 8,875 (6%) Total 137,539 * Not Specified: The location of the study was not provided by the Sponsor. (Data as of December 18, 2012) Locations of Recruiting Studies This chart shows the distribution of locations for recruiting studies registered on ClinicalTrials.gov. Total N = 29,400 studies (Data as of December 18, 2012) Legend for Recruiting Study location pie chart image Pie Color Location Non-U.S. Only (49%) U.S. Only (45%) Both U.S. Non-U.S. (6%) Distribution of locations for recruiting studies registered on ClinicalTrials.gov Location Number of Recruiting Studies and Percentage of Total Non-U.S. Only 14,378 (49%) U.S. Only 13,118 (45%) Both U.S. Non-U.S. 1,904 (6%) Total 29,400 (Data as of December 18, 2012) To Top Map of Studies Registered on ClinicalTrials.gov See Studies on a Map for an interactive map of studies that are registered on ClinicalTrials.gov. To Top Types of Registered Studies This table shows the number and types of studies that are registered and for which results are available on ClinicalTrials.gov. (Data as of December 18, 2012) Study and intervention types with number of registered studies and with number of studies having posted results Study and Intervention Type Number of Registered Studies and Percentage of Total Number of Studies With Posted Results and Percentage of Total*** Total 137,539 7,679 Interventional 111,598 (81%) 7,159 (93%) Type of Intervention* Drug or biologic 75,606 6,133 Behavioral, other 26,611 750 Surgical procedure 12,574 293 Device** 9,490 639 Observational 25,315 (18%) 520 (6%) Expanded Access 186 N/A * A study may include more than one type of intervention (that is, a single study may be counted more than once). Because of this, the sum of counts by type of intervention do not equal the total number of interventional studies. ** A total of 440 applicable device clinical trials were submitted as "delayed posting" under the Food and Drug Administration Amendments Act of 2007 (FDAAA). That is, the Responsible Party has indicated that such a trial includes a device not previously approved or cleared by the U.S. FDA for any use. These are not included in the count of trials with at least one device. *** Results are only required to be submitted for certain trials. For example, results submission is generally not required for trials of drugs, biologics, or devices that have not been approved by FDA; observational studies; and trials completed before 2008. N/A = not applicable To Top Number of Registered Studies Over Time The graph below shows the total number of studies registered on ClinicalTrials.gov since 2000, based on the First Received Date. The first version of ClinicalTrials.gov was made available to the public on February 29, 2000. (Data as of December 18, 2012) Key ICMJE: Indicates when the International Committee of Medical Journal Editors began requiring trial registration as a condition of publication under the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (URM) (September 2005). FDAAA: Indicates when the expanded registration requirements of FDAAA began and were implemented on ClinicalTrials.gov (December 2007). Years with numbers of registered studies Year Total Number of Registered Studies 2000 5,647 2001 7,000 2002 8,598 2003 10,279 2004 12,081 2005 25,041 2006 35,984 2007 49,399 2008 66,448 2009 83,636 2010 101,356 2011 119,482 (Data as of December 18, 2012) To Top Number of Registered Studies With Posted Results Over Time The graph below shows the number of registered studies with results posted on ClinicalTrials.gov, based on the Results First Received Date. ClinicalTrials.gov launched its results database in September 2008, at which time sponsors or investigators were allowed to begin submitting results for their registered studies. The results database was developed to accommodate results submission requirements outlined in FDAAA. (Data as of December 18, 2012) Years with numbers of registered studies having posted results Year Total Number of Registered Studies With Posted Results 2009 1,795 2010 3,459 2011 5,742 (Data as of December 18, 2012) This page last reviewed in August 2012 To Top 数据来源： http://clinicaltrials.gov/ct2/resources/trends See Studies on Map Map of All Studies in ClinicalTrials.gov Click on the map below to show a more detailed map (when available) or search for studies (when map not available). Region Name Number of Studies World 137539 Africa 3094 Central America 1827 East Asia 11668 Japan 2555 Europe 36903 Middle East 5582 North America 72205 Canada 10420 Mexico 1772 United States 65858 North Asia 2530 Pacifica 3834 South America 4650 South Asia 2472 Southeast Asia 2763 Hints: Click on a link to show a map of that region Click on a link to search for studies in that region. Use the back button to return to this list and try another region. Studies with no locations are not included in the counts or on the map. Studies with multiple locations are included in each region containing locations. See Studies on Map Map of All Studies in ClinicalTrials.gov Click on the map below to show a more detailed map (when available) or search for studies (when map not available). Region Name Number of Studies World 137539 East Asia 11668 China 3434 Hong Kong 771 Korea, Republic of 3902 Mongolia 6 Taiwan 2836 Hints: Click on a link to show a map of that region Click on a link to search for studies in that region. Use the back button to return to this list and try another region. Studies with no locations are not included in the counts or on the map. Studies with multiple locations are included in each region containing locations. 数据来源： http://clinicaltrials.gov/ct2/search/map?map=ES
维生素A 缺乏症的临床试验研究有21项（见下面的详细信息），唐研究员做的研究课题很普通，研究目的、研究方法和研究结果没有什么特别的。从PUBMED数据库中检索到维生素A缺乏症的临床试验文献有269篇（见下面的信息分析结果）。 转基因大米人体试验（唐广文的论文和临床试验报告） 唐广文的论文昭示儿童转基因大米实验背景 （建议大家读一读） http://blog.sciencenet.cn/home.php?mod=spaceuid=280034do=blogid=609726 论文昭示儿童转基因大米实验背景 http://www.ebiotrade.com/newsf/2012-9/201295142556143.htm 该课题组的具体研究分工： 1 唐广文教授设计实验，实施田间试验，监督数据分析，并编写了手稿； 2 胡余明研究员协调和监督研究；荫士安进行研究和收集样品； 3 王茵研究员审核研究设计和监督研究；Gerard E Dallal监督和实施统计分析； 4 Michael A Grusak生产内源性标记的水稻和菠菜； 5 Robert M Russell设计了这项研究，并担任研究医生。 研究是在中国湖南省的一所小学开展的，对象是年龄在6-8岁的健康小学生（有着正常的生化检测结果；如下），无寄生虫感染，或用阿苯达唑（葛兰素史克）治疗后证实无感染。大部分居民是本地农村的劳动人民，收入中等。48%的研究对象在治疗（无副作用）后被招募，在研究餐开始前的一个月参与研究。因此，研究时的所有研究对象经过实验室检测，均无寄生虫感染。当地每年对所有儿童进行健康评估和生物医学检测（白细胞计数、血红蛋白计数、血小板计数、红细胞计数和红细胞压积）。生物通 www.ebiotrade.com 为了评估研究的样本大小，我们使用了过去美国的菠菜或β-胡萝卜素胶囊研究（26,27）和中国的深绿色蔬菜研究（28）进行power计算。我们发现，为了确定两个类别的差异——边缘和正常维生素A摄入，我们需要每个类别30个的样本大小，为了评估各种来源的食物机制的效果（菠菜、黄金大米和β-胡萝卜素胶囊），我们需要每组10个。考虑到对象退出研究的可能性，我们提议边缘维生素A组有36个对象，正常维生素A组有36个对象，而菠菜组、大米组和β-胡萝卜素胶囊组每组有12个。 在筛查的总共112个对象中，72个参加了研究，并从68个对象中采集了足够的血清样本（每个对象在1-5个时间点之间变化），便于HPLC和气相色谱-质谱分析。对象的人体测量是在全中国这一年龄组所报告的数据范围内（29）。 研究招募过程和程序经过了美国机构审查委员会-塔尔茨医学中心和中国浙江省医学科学院伦理审查委员会的批准。所有家长和学生都同意参加本研究。 致谢： 我们感谢所有中国湖南参与这一研究的志愿者，以及主厨、护士和中国长沙的湖南省疾病预防与控制中心相关人员。 作者分工如下： Guangwen Tang负责实验设计，实施田间实验，监督数据分析并且撰写论文 Yuming Hu：协调并监督这项研究 Shi-an Yin：进行研究并收集样本 Yin Wang：评估实验设计并进行监督 Gerard E Dallal：监督并进行统计学分析 Michael A 黄金大米usak：生产带标记的大米和菠菜 Robert M Russell：设计实验并作为本研究中的医师 所有的作者都看过论文手稿，没有作者与该研究存在利益冲突。 http://blog.sciencenet.cn/blog-280034-609409.html 2012年最新的这篇题为“β-Carotene in Golden Rice is as good as β-carotene in oil at providing vitamin A to children”的文章一经过公布，就引起了众多关注，文章主要是对儿童进行试验，试验分三组，一共有68个年龄6-8岁的儿童，在35天时间里，三组儿童分别摄入这种试验大米，菠菜，和β-胡萝卜素的胶囊。结论是在提供给儿童维生素A的方面，GR大米中β-胡萝卜素与胶囊中的一样有效，并且优于菠菜。 关于“Golden Rice”（转基因黄金大米，GR）的报道近期掀起了轩然大波，目前最新进展是相关文章（β-Carotene in Golden Rice is as good as β-carotene in oil at providing vitamin A to children）中第二，第三和第四作者（均为中方作者）都否认了曾参与这项研究，称“之前既没有听说与该篇论文相关的任何信息，也没有看过论文的内容，更不知道为何自己的名字会出现在论文的作者之中”，事件进展扑朔迷离，在进一步调查结果出来之前，让我们来看看相关发表的论文。 http://www.ebiotrade.com/newsf/2012-9/201295115024123.htm 安德莉亚·格罗斯曼在声明中说 ，“这项试验的目的是测试黄金大米作为在发展中国家一个非常严重健康问题(维生素A缺乏)的部分解决方案的可行性。” 维生素A 缺乏症是因体内缺乏维生素A而引起的以眼和皮肤病变为主的全身性疾病，多见于1～4岁小儿；最早的症状是暗适应差，眼结合膜及角膜干燥，以后发展为角膜软化且有皮肤干燥和毛囊角化，故又称夜盲症、干眼病、角膜软化症。 Vitamin A Equivalence of Plant Carotenoids in Children This study has been completed. Study NCT00680212 Information provided by Tufts University First Received on May 16, 2008. Last Updated on February 17, 2009 History of Changes Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study: Conditions listed in this trial Vitamin A Deficiency Additional conditions recognized in this trial Night Blindness More general conditions related to this trial Avitaminosis Deficiency Diseases Eye Diseases Malnutrition Nutrition Disorders Vision Disorders Interventions listed in this trial dietary carotenoids Additional drug interventions recognized in this trial Beta Carotene Carotenoids Retinol palmitate Vitamin A Vitamins More general drug interventions related to this trial Anticarcinogenic Agents Antineoplastic Agents Antioxidants Growth Substances Micronutrients Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Protective Agents Therapeutic Uses Sponsors listed in this trial Tufts University http://clinicaltrials.gov/ct2/show/related/NCT00680212 Found 21 studies with search of: "Vitamin A Deficiency" Hide studies that are not seeking new volunteers. Hide studies with unknown recruitment status. Display Options Rank Status Study 1 Completed Treatment of Congenital Stationary Night Blindness With an Alga Containing High Dose of Beta Carotene Condition: NightBlindness Intervention: DietarySupplement:algaDunaliellabardawil 2 Completed Efficacy of Vitamin A in Fortified Extruded Rice in School Children Condition: VitaminADeficiency Intervention: Dietary Supplement: Triple fortified extruded tice (Fe, Zn and vitamin A) 3 Recruiting Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function Condition: VitaminADeficiency Interventions: DietarySupplement:retinylpalmitate; DietarySupplement:Placebo 4 Recruiting Efficacy of Yellow Cassava to Improve Vitamin A Status of Kenyan School Children Condition: VitaminADeficiency Interventions: Other:Yellowcassava; Other:Whitecassava 5 Completed An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand Conditions: VitaminADeficiency; IronDeficiency; ZincDeficiency Intervention: DietarySupplement:fortifiedextrudedrice 6 Completed Impact of Maternal Supplementation With Dual Megadose of Vitamin A Conditions: Hypovitaminosis; VitaminADeficiency Interventions: DietarySupplement:vitaminA; DietarySupplement:Placebo 7 Active, not recruiting Vitamin A Bioavailability in Lactating Women With Marginal Vitamin A Status Condition: VitaminADeficiency Interventions: Other:0mgretinolactivityequivalents; Other:12mgofBC; Other:6mgofCX; Other:1.0mgRAE 8 Completed Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission Conditions: HIVInfections; VitaminADeficiency; HIVSeronegativity Intervention: Drug:VitaminA 9 Completed Vitamin A Equivalence of Plant Carotenoids in Children Condition: VitaminADeficiency Interventions: DietarySupplement:dietarycarotenoids; Dietary Supplement: spinach, rice, and synthetic beta-carotene 10 Unknown † Single-dose Postpartum Vitamin A Supplementation of Mothers and Neonates Conditions: VitaminADeficiency; HIV Intervention: Drug:VitaminA(retinylpalmitate) 11 Completed Retinol Equivalence of Plant Carotenoids in Children Condition: VitaminADeficiency Intervention: 12 Completed Has Results Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh Conditions: VitaminADeficiency; MaternalMortality; InfantMortality Intervention: Dietary Supplement: Vitamin A or Beta-Carotene Supplements 13 Completed Trial of the Impact of Vitamin A on Maternal Mortality Conditions: VitaminADeficiency; MaternalMortality; MaternalMorbidity Intervention: DietarySupplement:VitaminA 14 Completed Impact of Consumption of Orange-fleshed Sweet Potatoes on the Vitamin A Status of Bangladeshi Women of Reproductive Age Condition: VitaminADeficiency Intervention: Behavioral: Consumption of orange-fleshed sweet potatoes 15 Terminated Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh Conditions: InfantMortality; VitaminADeficiency Intervention: Drug:vitaminAsupplementation(50,000IU) 16 Recruiting Effect of Vitamin A Supplementation on Immune Responses in Human Neonates Condition: VitaminADeficiency Intervention: Dietary Supplement: Vitamin A (retinyl palmitate). 17 Completed Dietary Vitamin A Requirement in Chinese Children and the New Technology of Dietary Assessment Condition: VitaminADeficiency Intervention: 18 Completed Vitamin A Absorption From Cassava in Women Condition: VitaminADeficiency Interventions: Other: Beta-Carotene bio-fortified cassava porridge without oil; Other: Beta-Carotene bio-fortified cassava porridge with oil; Other: White cassava porridge with retinyl palmitate reference dose 19 Completed Newborn Vitamin A (VA) Supplementation Pilot Project, Pakistan Condition: VitaminADeficiency Interventions: DietarySupplement:VitaminA; DietarySupplement:Placebo 20 Active, not recruiting Nutributter Programming to Prevent Undernutrition: an Evaluation Condition: Undernutrition Interventions: DietarySupplement:NutributterProgram; Other:IntegratedPackage Found 21 studies with search of: "Vitamin A Deficiency" Hide studies that are not seeking new volunteers. Hide studies with unknown recruitment status. Display Options Rank Status Study 21 Completed A Study on Immunological Effect of Vitamin A and Zinc in a Placebo Controlled 4 Cell Trial Conditions: Immunity; Diarrhea; RespiratoryTractInfections Intervention: Drug:Zinc,orVitaminAorboth 详细信息见 http://clinicaltrials.gov/ct2/results?cond=%22Vitamin+A+Deficiency%22pg=1 Found 21 studies with search of: "Vitamin A Deficiency" No Query Suggestions Recognized Terms and Synonyms: Vitamin A Deficiency: 21studies deficiencies disease vitamins deficiencies vitamins deficiency of vitamin a hypovitaminosis a keratomalacia night blindness retinol deficiency vitamin a deficiencies vitamin deficiency disease xerotic keratitis Related Terms: Click on a related term to refine your search. This will narrow your search by adding an additional search term. If your search becomes too narrow (finds too few studies), broaden it by removing search terms with the Refine Search page. B beta-carotene C carotenes cassava N night blindness O of vitamin a deficiency P palmitates retinol palmitate provitamin a R retinol retinol activity equivalent retinol equivalent retinol palmitate retinyl palmitate S spinach V vitamin a deficiencies of vitamin a deficiency vitamin a intake 检索策略： 1 "vitamin a deficiency维生素A缺乏" OR "vitamin a deficiency" 检索结果 5619篇 2 ("vitamin a deficiency" OR "vitamin a deficiency" ) AND Clinical Trial临床试验 检索结果269篇 信息分析平台： http://arrowsmith.psych.uic.edu/cgi-bin/arrowsmith_uic/AnneOTate_summarize.cgi?ID=31269t=fw=ch 科研论文信息分析结果： Important words 重要词汇 词频Frq 1 vitamin 4661 2 retinol 1250 3 xerophthalmia 287 4 bitot 116 5 hypovitaminosis 216 6 deficiency 3097 7 retinyl 255 8 provitamin 113 9 keratomalacia 60 10 vad 252 11 micronutrient 244 12 mrdr 24 13 deficient 1259 14 carotene 353 15 avitaminosis 89 16 xerophthalmic 24 17 retinoic 514 18 a-deficient 41 19 blindness 368 20 supplementation 664 Topics 研究主题分布 Frq 1 Vitamin A Deficiency 4525 2 Vitamin A 2643 3 Liver 718 4 Diet 454 5 Xerophthalmia 370 6 Tretinoin 350 7 Nutritional Status 342 8 Body Weight 306 9 Carotenoids 306 10 Prevalence 289 11 Nutrition Disorders 258 12 India 253 13 Rats, Inbred Strains 252 14 Dietary Supplements 235 15 Developing Countries 217 16 Retinol-Binding Proteins 215 17 Risk Factors 209 18 Cross-Sectional Studies 195 19 Night Blindness 190 20 Iron 179 Author 作者分布 frq 1 Sommer A 86 2 West KP 58 3 Ross AC 53 4 Semba RD 52 5 Wolf G 48 6 West CE 44 7 Muhilal 36 8 Olson JA 36 9 De Luca LM 35 10 Biesalski HK 32 11 Reddy V 32 12 Amedee-Manesme O 30 13 DeLuca HF 29 14 Underwood BA 29 15 Bloem MW 27 16 Tanumihardjo SA 26 17 Katz J 25 18 Russell RM 25 19 Zile MH 24 20 Chytil F 23 Affiliations 研究机构分布 frq 1 USA 420 2 Baltimore 128 3 India 115 4 France 95 5 Department of Biochemistry 93 6 Department of Ophthalmology 92 7 Department of Pediatrics 91 8 Japan 66 9 Boston 61 10 London 53 11 Department of Nutrition 52 12 The Netherlands 52 13 Canada 48 14 UK 46 15 New York 45 16 MD 21205 44 17 Brazil 38 18 Department of Human Nutrition 38 19 Department of International Health 38 20 Department of Medicine 37 Journals 期刊分布 frq 1 J Nutr 280 2 Am J Clin Nutr 230 3 Int J Vitam Nutr Res 117 4 Nutr Rev 91 5 Lancet 85 6 Br J Nutr 76 7 Eur J Clin Nutr 68 8 Biochem J 63 9 Indian Pediatr 61 10 Arch Latinoam Nutr 50 11 Biochim Biophys Acta 49 12 Food Nutr Bull 49 13 Vopr Pitan 49 14 Ukr Biokhim Zh 47 15 Invest Ophthalmol Vis Sci 42 16 J Trop Pediatr 42 17 Public Health Nutr 42 18 Br J Ophthalmol 40 19 Indian J Pediatr 40 20 Proc Soc Exp Biol Med 35 Years年代分布 1 2012 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 2 2011 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 3 2010 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 4 2009 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 5 2008 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 6 2007 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 7 2006 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 8 2005 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 9 2004 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 10 2003 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 11 2002 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 12 2001 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 13 2000 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 14 1999 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 15 1998 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 16 1997 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 17 1996 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 18 1995 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 19 1994 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 20 1993 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Topics 文献聚类 Frq Most recent articles 347 1 Liver 718 2 Diet 454 3 Xerophthalmia 370 4 Tretinoin 350 5 Nutritional Status 342 6 Carotenoids 306 7 Body Weight 306 8 Prevalence 289 9 Nutrition Disorders 258 10 India 253 11 Rats, Inbred Strains 252 12 Developing Countries 217 13 Retinol-Binding Proteins 215 14 Epithelium 178 15 Vitamin E Deficiency 168 Miscellaneous 2133 参考文献 • 评论：谁隐瞒了“儿童试验 转基因 大米”真相 • 原论文全文： 转基因 大米儿童实验（一） • 利用儿童实验的 转基因 大米论文全文（三） • 湖南农业厅：从未批准 转基因 大米试验 • 转基因 大米试验部分涉事家长称不知是试验 • 利用儿童实验的 转基因 大米论文全文（四） • 利用儿童实验的 转基因 大米论文全文（二） • 一论文利用中国儿童做 转基因 试验引争议 • 转基因 研究难以避免人体试验 • 转基因 大米人体试验中美当事人说法不一致 • 国家动物 转基因 技术研究中心落户内蒙古大学 • 转基因 大米试验发生了什么 • 转基因 大米不是毒，但是是风险，以及无罪推定 • 小学生 转基因 试验陷“罗生门” • 评论： 转基因 大米试验需要实质性回应 • 美大学承认用中国儿童做 转基因 大米试验 • 制备 转基因 小鼠过程中的若干技巧 • 湖南衡阳称无学生涉及 转基因 人体试验 • 转基因 水稻的基因逃逸“不可避免但缓慢” • 两头 转基因 “克隆牛”在京出生喝进口奶粉 • 科学家研制出首例 转基因 芒草 • 农业 转基因 管理各国迥异 • 转基因 玉米：有望在中国大放光芒 • 全世界78%的 转基因 作物生产自美洲大陆 • 害虫突变可能会危及 转基因 作物的功效 • 美国新一代 转基因 大豆悄然上市FDA为其开绿灯 • 转基因 细菌阻止蚊子传播疟疾 • 盖茨基金会千万美元资助英国 转基因 农业研究 • 美国民众网络请愿拒绝“ 转基因 蚊子” • 用 转基因 蚊子解决登革热等问题 • “消费者无需担忧有“准生证”的 转基因 食品” • 袁隆平称不应该全否定 转基因 • 中国 转基因 主粮安全问题是是非非十年 • 美国科学家培育出世界上第一批 转基因 婴儿 • 疾控专家：有“准生证”的 转基因 食品可放心吃 • 元勋子女斗法 转基因 • 中国 转基因 稻违规扩散 • 转基因 大豆油成北京学校食堂主力
我建议：在没有取得充分证据前，科学网的博主和读者不要急于下结论，先仔细看看唐广文研究员的原始论文和临床试验报告。 ----- 许博主 美国塔夫茨大学回应：正在调查 本报驻美国记者吴成良 记者9月1日向唐广文(音)博士发去电子邮件，就“黄金大米”试验疑云请其作出澄清。记者在9月2日收到了塔夫茨大学健康科学中心公共关系助理主任安德莉亚·格罗斯曼发来的电邮，就该事件做了声明，同时附上了“唐广文和她的同事2012年8月1日和2009年先后发表在《美国临床营养学期刊》(AJCN)网站上的两篇相关论文”。 安德莉亚·格罗斯曼在声明中说，“这项试验的目的是测试黄金大米作为在发展中国家一个非常严重健康问题(维生素A缺乏)的部分解决方案的可行性。” 格罗斯曼在声明中说：“这项研究聚焦一小组健康的中国儿童，年龄在6至8岁。中国儿童血液中维生素A含量低是普遍现象。试验前征得了所有儿童家长的同意。所有参与试验的儿童都接受了一定形式的维生素A。” 但这份声明较为含糊。声明仅称参与试验的儿童都接受了一定形式的维生素A，未说明试验的儿童是否吃了黄金大米。 美国当地时间9月4日上午10时左右，本报驻美国记者接到格罗斯曼亲自打来的电话。格罗斯曼称，正在召集相关部门人员开会了解此事，这需要一定时间，因为他们需要在联系有关方面和人员之后才能给出回应，而唐广文暂时不在办公室。最快可能要到当地时间4日下午才能给记者回复。 http://international.dbw.cn/system/2012/09/05/054211328_03.shtml 当事人否认转基因大米试验使用“黄金大米”唐广文被疑学术造假 http://env.people.com.cn/n/2012/0905/c1010-18925670.html 2012 American Society for Nutrition β-Carotene in Golden Rice is as good as β-carotene in oil at providing vitamin A to children 1 , 2 , 3 , 4 Guangwen Tang , Yuming Hu , Shi-an Yin , Yin Wang , Gerard E Dallal , Michael A Grusak , and Robert M Russell + Author Affiliations 1 From the Carotenoids Health Laboratory, USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA (GT, GED, and RMR); the Hunan Province Center for Disease Control and Prevention, Changsha, China (YH); Maternal Child Nutrition, National Institute for Nutrition and Food Safety, Beijing, China (SY); the Zhejiang Academy of Medical Sciences, Hangzhou, China (YW); the USDA-ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX (MAG); and the Office of Dietary Supplement s , NIH, Bethesda, MD (RMR). + Author Notes ↵ 2 Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the US Department of Agriculture, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. ↵ 3 This material is based on work supported by the US Department of Agriculture under Cooperative Agreements 581950-9-001, 58-6250-6-001, and 581950-7-707; by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases, NIH (NIDDK DK620021); and by a grant on spinach and pure labeled β-carotene from the National Technology Research and Development Program in the 11th Five Year Plan of China (2008BAI58B03). ↵ 4 Address correspondence to G Tang, Jean Mayer USDA, Human Nutrition Research Center on Aging, Tufts University, 711 Washington Street, Boston, MA 02111. E-mail: guangwen.tang@tufts.edu . Abstract Background: Golden Rice (GR) has been genetically engineered to be rich in β-carotene for use as a source of vitamin A. Objective: The objective was to compare the vitamin A value of β-carotene in GR and in spinach with that of pure β-carotene in oil when consumed by children. Design: Children ( n = 68; age 6–8 y) were randomly assigned to consume GR or spinach (both grown in a nutrient solution containing 23 atom% 2 H 2 O) or β-carotene in an oil capsule. The GR and spinach β-carotene were enriched with deuterium ( 2 H) with the highest abundance molecular mass (M) at M β-C + 2 H 10 . Retinyl acetate in an oil capsule was administered as a reference dose. Serum samples collected from subjects were analyzed by using gas chromatography electron-capture negative chemical ionization mass spectrometry for the enrichments of labeled retinol: M retinol +4 (from β-carotene in oil), M retinol +5 (from GR or spinach β-carotene), and M retinol +10 (from retinyl acetate). Results: Using the response to the dose of retinyl acetate (0.5 mg) as a reference, our results (with the use of AUC of molar enrichment at days 1, 3, 7, 14, and 21 after the labeled doses) showed that the conversions of pure β-carotene (0.5 mg), GR β-carotene (0.6 mg), and spinach β-carotene (1.4 mg) to retinol were 2.0, 2.3, and 7.5 to 1 by weight, respectively. Conclusions: The β-carotene in GR is as effective as pure β-carotene in oil and better than that in spinach at providing vitamin A to children. A bowl of ∼100 to 150 g cooked GR (50 g dry weight) can provide ∼60% of the Chinese Recommended Nutrient Intake of vitamin A for 6–8-y-old children. This trial was registered at www.clinicaltrials.gov as NCT00680212 . Received November 17, 2011. Accepted June 21, 2012. http://ajcn.nutrition.org/content/96/3/658.abstract 8月31日，有网文称，美国一专业网站刊登的论文透露，美国塔夫茨大学一科研机构2008年在湖南省一所小学进行过转基因大米(黄金大米)人体试验，该网文随即在国内外引发强烈关注。 记者了解到，8月1日，《美国临床营养学杂志》网站发表了一篇名为《黄金大米中的β-胡萝卜素与油胶囊中的β-胡萝卜素对儿童补充维生素A同样有效》的论文。 论文称，为了比较儿童摄入“黄金大米”、菠菜和β-胡萝卜素油胶囊对补充维生素A有何不同，美国塔夫茨大学、湖南疾病预防控制中心、中国疾控中心营养与食品安全所、浙江医学科学院等工作机构的研究人员2008年共同在湖南省的一所小学进行试验，针对的是6到8岁的健康的在校小学生。 论文同时称，研究所用材料——黄金大米和菠菜都是在美国生产、处理和蒸煮，然后冷藏运至中国实验所在地加热后供小学生食用。 论文称，所有的作者均审查了原稿。 该论文共有7名作者。据记者了解，论文第一作者唐广文(音)为美国塔夫茨大学研究员，论文第二作者胡余明为中国湖南省疾控中心工作人员，第三作者荫士安为中国疾控中心研究员，第四作者王茵为浙江医学科学院研究人员。其他3位作者为杰拉德·戴罗尔、米切尔·格鲁萨克、罗伯特·罗素。另据了解，所谓“黄金大米”是一种转基因大米，因呈黄色而得名。 http://international.dbw.cn/system/2012/09/05/054211328.shtml 人民日报:美国转基因大米实验食材来自湖南当地 发布时间: 2012-09-05 07:45来源: 人民日报 进入电子报 http://news.cnhubei.com/xw/gn/201209/t2213536.shtml 美国课题组织者承认给湖南小学生吃转基因大米 http://news.hf365.com/system/2012/09/05/011732039_01.shtml 美高校回应“黄金大米”事件：试验征得中方家长同意 http://news.cnnb.com.cn/system/2012/09/05/007446371.shtml Vitamin A Equivalence of Plant Carotenoids in Children This study has been completed. First Received on May 16, 2008. Last Updated on February 17, 2009 History of Changes Sponsor: Tufts University Information provided by: Tufts University ClinicalTrials.gov Identifier: NCT00680212 Purpose Our objectives will be to test the following hypotheses and to make the following determinations: (1) The absorption and bio-conversion of provitamin A carotenes taken by children are different between spinach, Golden Rice, and -C in oil capsules. (2) The absorption of provitamin A carotenes and their bioconversion to vitamin A are different in children with or without adequate vitamin A nutrition. (3) To define the vitamin A equivalence(s) of dietary spinach, Golden Rice, and a -C in oil dose by using an isotope reference method in children with or without adequate vitamin A nutrition and to compare those values with values derived from model based compartmental analysis. (4) To determine the number and time of blood samples needed for future studies in various field settings on the retinol equivalence of a large number of plant sources. Condition Intervention Phase Vitamin A Deficiency Dietary Supplement: dietary carotenoids Dietary Supplement: spinach, rice, and synthetic beta-carotene Phase 2 Study Type: Interventional Study Design: Allocation:Randomized EndpointClassification:Bio-equivalenceStudy InterventionModel:FactorialAssignment Masking:OpenLabel PrimaryPurpose:BasicScience Official Title: Phase 2 Study of VITAMIN A EQUIVALENCE OF PLANT CAROTENOIDS IN CHILDREN Resource links provided by NLM: Genetics Home Reference related topics: carbamoylphosphatesynthetaseIdeficiency MedlinePlus related topics: VitaminA Drug Information available for: Retinol VitaminApalmitate betacarotene U.S. FDA Resources Further study details as provided by Tufts University: Primary Outcome Measures: conversion efficiency of b-C to retinol Estimated Enrollment: 72 Study Start Date: July 2008 Study Completion Date: January 2009 Primary Completion Date: January 2009 (Final data collection date for primary outcome measure) Arms Assigned Interventions 1 dietary carotenoids Dietary Supplement: dietary carotenoids spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene 0.5 mg oil capsule Dietary Supplement: spinach, rice, and synthetic beta-carotene spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene, 0.5 mg oil dose Other Name: dietary carotenoids Detailed Description: This project is to determine the vitamin A value (equivalence) of dietary provitamin A carotenes from spinach, Golden Rice, and pure -carotene (-C) in oil. These experiments will be conducted in children (ages 6-8) with/without adequate (marginal deficiency) vitamin A nutrition. As plant provitamin A carotenoids are a major and safe vitamin A source for a vast population in the world, it is essential to determine the efficiency of provitamin A carotenoid (mainly -C) conversion to vitamin A. By introducing -C into rice endosperm, Golden Rice may directly benefit consumers by providing vitamin A nutrition. Our investigation uses hydroponically grown, deca-deuterium labeled spinach and Golden Rice, synthetic -C-d10 and a vitamin A isotope reference, C13 labeled retinyl acetate (13C10-RAc), to evaluate the bioavailability and the bioconversion of plant provitamin A carotenes to retinol as compared with -C in oil capsules in vivo. Seventy-two children each will take two meals, breakfast containing 13C10-RAc dose (0.5mg in 0.2g oil capsule) and lunch containing spinach containing 1 mg -C (along with white rice), or Golden Rice containing 0.5mg -C (along with light colored vegetables), or -C oil capsules containing 0.5 mg -C in 0.2g oil (along with white rice and light colored vegetables) on the first day of the study. Blood samples will be collected at 1 3, 7, 14, and 21 days after the study doses. The enrichment of labeled -C and labeled retinol in human circulation will be determined using advanced liquid chromatography / mass spectrometry and gas chromatography / mass spectrometry. Through the applications of these novel technologies, we will be able to determine the relative biological activities of endogenous carotenoids; that is, the vitamin A value of spinach, Golden Rice, and -C in oil capsules for children with/without vitamin A malnutrition. This study will be of importance in planning vitamin A deficiency prevention strategies and also will provide useful information regarding the potential efficacy of a bioengineered crop to provide vitamin A nutrition. Eligibility Ages Eligible for Study: 6 Years to 8 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: healthy children Exclusion Criteria: food allergy parasitic infection Contacts and Locations Please refer to this study by its ClinicalTrials.gov identifier: NCT00680212 Locations United States, Massachusetts USDA Human Nutrition Research Center on Aging, Tufts Uni. Boston, Massachusetts, United States, 02111 Sponsors and Collaborators Tufts University Investigators Principal Investigator: Guangwen Tang, Ph. D Tufts University More Information No publications provided Responsible Party: Guangwen Tang, Tufts University ClinicalTrials.gov Identifier: NCT00680212 History of Changes Other Study ID Numbers: IRB 8458, R01DK60021 Study First Received: May 16, 2008 Last Updated: February 17, 2009 Health Authority: United States: Institutional Review Board Keywords provided by Tufts University: dietary beta-carotene vitamin A status intrinsically labeled plant foods Additional relevant MeSH terms: Vitamin A Deficiency Night Blindness Avitaminosis Deficiency Diseases Malnutrition Nutrition Disorders Vision Disorders Eye Diseases Carotenoids Retinol palmitate Vitamin A Vitamins Beta Carotene Antioxidants Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents Physiological Effects of Drugs Micronutrients Growth Substances Anticarcinogenic Agents Antineoplastic Agents Therapeutic Uses ClinicalTrials.gov processed this record on September 03, 2012 http://clinicaltrials.gov/show/NCT00680212 《美国临床营养学期刊》 American Journal of Clinical Nutrition http://www.ajcn.org/ Country : United States Subject Area : Agricultural and Biological Sciences | Medicine Subject Category : Food Science , Medicine (miscellaneous) Publisher : American Society for Clinical Nutrition, Inc. . Publication type : Journals. ISSN : 00029165, 19383207 Coverage: 1952-2011 影响因子： 6.669 H Index: 186 Scope: The purpose of The American Journal of Clinical Nutrition (AJCN) is to publish original research studies relevant to human and The purpose of The American Journal of Clinical Nutrition (AJCN) is to publish original research studies relevant to human and clinical nutrition. Well-controlled clinical studies that describe scientific mechanisms, efficacy, and safety of dietary interventions in the context of disease prevention or a health benefit will be considered. Public health and epidemiologic studies relevant to human nutrition, and innovative investigations of nutritional questions that employ epigenetic, genomic, proteomic, and metabolomic approaches are encouraged. Solicited editorials,book reviews, solicited or unsolicited review articles, invited controversy position papers, and letters to the Editor that relate to prior AJCN articles are essential components of the AJCN. ( source ) Show full scope
标签: 临床试验
